Search results: (10000)
News Successful Long-Term Subcutaneous Prophylaxis of Hereditary Angioedema – Case Study
Hereditary angioedema (HAE), arising from a deficiency of C1 inhibitor (C1-INH), clinically manifests as swelling of the subcutaneous tissue and mucous membranes. The standard prophylactic therapy consists of intravenous (i.v.) substitution of C1-INH. We present a case study of successful long-term subcutaneous (s.c.) prophylaxis in a patient who had to discontinue i.v. prophylaxis.
News Participation in sports activities, frequency and severity of sports injuries in children with hemophilia
Children with hemophilia used to be discouraged from engaging in sports activities due to the potential increased risk of bleeding. The introduction of prophylaxis into routine practice has improved the possibility for children to participate in various sports activities. A study conducted by Dutch authors evaluated the involvement of boys with hemophilia in sports activities and their potential link with sports injuries and bleeding.
News Sport Therapy as Part of Hemophilia Management
A study by authors from the University of Wuppertal in Germany specifically examined the impact of a half-year programmed sport therapy on the subjective physical performance and quality of life of individuals with hemophilia.
News Can identifying alpha-1 antitrypsin deficiency before liver transplantation extend survival?
Alpha-1 antitrypsin deficiency (AATD) can manifest (among other things) as liver cirrhosis. The study presented below examined the survival of patients diagnosed with AATD before and after liver transplantation.
News Population Pharmacokinetic Model in Patients with von Willebrand Disease
Dutch authors presented a potential population pharmacokinetic model describing levels of von Willebrand factor and coagulation factor VIII during and after surgical procedures in patients with von Willebrand disease.
News How do Hemodialysis Patients Perceive the Coronavirus Pandemic? Survey Results
Hemodialysis patients are at higher risk of SARS-CoV-2 infection due to repeated visits to medical facilities. Additionally, these are often older and comorbid patients living in nursing homes. This study, presented below, examines how these patients perceived anti-epidemic measures during the first wave of the pandemic and how this extraordinary situation impacted their mental state.
News Lurasidone in the Treatment of Adolescent Schizophrenia: How Does It Compare with Other Atypical Antipsychotics?
A meta-analysis of 13 studies comparing lurasidone with other atypical antipsychotics in monotherapy for adolescent patients with schizophrenia evaluated the effectiveness of the treatment, the rate of weight gain, and the frequency of medication discontinuation for each modality.
News Shared Decision-Making on Kidney Function Replacement
Peritoneal dialysis (PD) is not a new development, but its significance is becoming increasingly recognized. Until recently, we may not have fully appreciated its value, but in light of the global threat posed by the current pandemic, its importance is starkly clear. PD is an accessible solution designed for home care and allows patients to avoid visits to healthcare facilities to some extent.
News Does SGLT2 Inhibitor Administration Benefit Diabetics with Low Cardiorenal Risk?
There is growing evidence of the cardiorenal protective effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i, also known as gliflozins), which were developed as antihyperglycemic drugs for the treatment of type 2 diabetes. These antidiabetic medications are recommended for patients with heart or renal disease or at high risk of these complications. However, is it worthwhile to consider their use in diabetics as part of long-term primary cardiorenal prevention? Israeli authors sought the answer to this question.
News Hydroresponsive Dressings for Acute and Hard-to-Heal Wounds
A recently published review of clinical evidence from nearly three dozen studies demonstrates successful debridement and cleansing of various hard-to-heal wounds using HydroClean hydroresponsive dressing, with favorable healing outcomes.
News Prim. Pavel Jindra: Biosimilars are an accessible and effective treatment modality in hematooncology
“Based on our experience so far, biosimilars represent an effective and safe alternative to original molecules. We are not afraid to use them anywhere in approved indications, and we are not afraid of switching either. Biosimilars are a significant step towards greater accessibility of hematooncological treatment for a wide group of patients,” states the head of the Hematology-Oncology Department of FN Plzeň, MUDr. Pavel Jindra, Ph.D., in our current interview.
News Addition of ixazomib to lenalidomide and dexamethasone in multiple myeloma − Data from real-world Czech practice
A group of Czech and Slovak experts led by Associate Professor Jiří Minařík from the Hemato-Oncology Clinic of the Faculty of Medicine UP and University Hospital Olomouc published the final results of an observational study evaluating the addition of ixazomib to the combination with lenalidomide and dexamethasone in patients with relapsing/refractory multiple myeloma (RRMM). This involves experiences from real clinical practice, with data obtained from the Czech Registry of Monoclonal Gammopathies.
News Impact of Tofacitinib on the Quality of Life of Patients with Ulcerative Colitis
Tofacitinib is an oral Janus kinase (JAK) inhibitor used in the treatment of certain rheumatic diseases and ulcerative colitis (UC). The work presented at this year's 18th congress of the European Crohn's and Colitis Organization (ECCO) in Copenhagen, Denmark, focused on its impact on the quality of life in terms of physical and mental functions in patients with UC.
News Cost Effectiveness of FVIII Substitution Versus Non-Factor Therapy for Hemophilia A
With new treatment options for hemophilia A without inhibitors, the question of cost-effectiveness of different treatment approaches arises. The results of a model comparing replacement therapy and emicizumab in terms of cost-effectiveness were presented at a recently held ASH conference.
News Dosing and Consumption of rFVIII Products with Extended Half-life in Patients with Hemophilia A in Real-World Practice
Based on real-world data from the USA, a recently published study compared two recombinant human factor VIII (rFVIII) products with extended half-life (EHL) – efmoroctocog alfa and rurioctocog alfa pegol, in terms of dosing frequency, weekly consumption, and dose variability.
News Administration of Erdosteine after Severe COVID-19 in the Early Period after Discharging Patients from the Healthcare Facility
Erdosteine is a mucomodulatory drug used in the treatment of various acute and chronic respiratory diseases. According to available evidence, its mechanism of action is complex, encompassing not only a mucolytic effect but also antioxidant and antibacterial properties. Two clinical studies evaluated changes in respiratory distress parameters and quality of life in patients using this medication in the early period after discharge from a healthcare facility where they were hospitalized due to severe COVID-19.
News Consolidation therapy with brentuximab vedotin after autologous stem cell transplantation in patients with relapsed/refractory Hodgkin lymphoma
At the 12th International Symposium on Hodgkin Lymphoma (ISHL), held in October 2022 in Cologne, results of a Czech study evaluating the efficacy and safety of consolidation therapy with brentuximab vedotin in patients after autologous stem cell transplantation were presented.
News Prevention and Treatment of Thromboembolism in the Elderly
Despite advances in the prevention and treatment of venous thromboembolism, morbidity and mortality associated with this condition remain high in certain risk groups. An international expert group focused on the elderly in its analysis published in the Thrombosis Journal.
News Modern View on Schizophrenia Therapy Through the Lens of Lurasidone
At the psychiatric symposium titled 'Chance for a Better Quality of Life with a Schizophrenia Diagnosis', which took place on October 18, 2021, in Prague, Professor of Psychiatry and Molecular Biology Christoph U. Correll from the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell spoke. His lecture included insights on current approaches to schizophrenia therapy and key information on one of the newest antipsychotics - lurasidone.
News Is there a link between Parvovirus B19 infection and autoimmune thyroid diseases?
Autoimmune thyroid diseases are among the most common autoimmune disorders, with a worldwide prevalence of around 10%. The study presented below, recently published in the International Journal of Endocrinology and Metabolism, examined the connection between Parvovirus B19 infection (the cause of erythema infectiosum in children) and these diseases.
News INFOGRAPHIC: Determining the Target Intraocular Pressure in Glaucoma Therapy
The goal of glaucoma treatment is to preserve the visual field and the quality of life of patients. Currently, the only approach to preserving the visual field of patients is to reduce intraocular pressure (IOP). Its target value should be determined for each patient with consideration of individual risk factors. The following comprehensive infographic shows which factors should be considered according to the current recommendations of the European Glaucoma Society (EGS).
News Efficacy and Safety of Two Pharmacokinetically-Driven Prophylactic Regimens in People with Hemophilia A
Standard prophylaxis for bleeding in hemophilia A, based on the administration of coagulation factor VIII (FVIII), depends on the patient's weight, the severity of the coagulation factor deficiency, and the nature of bleeding episodes. The current trend, however, is an individualized approach in prophylaxis, which can improve clinical outcomes and optimize bleeding disorder therapy. A clinical study evaluated the efficacy and safety of two prophylactic regimens with different target trough levels of FVIII.
News Pharmacokinetics and Safety of Bilastine 10 mg in Children Aged 6–11 Years
The second-generation antihistamine bilastine is approved in Europe for the treatment of allergic rhinoconjunctivitis and urticaria from the age of 6 years. Recently, results from two post hoc analyses on the pharmacokinetics and safety of bilastine in children aged 6–11 years have been published.
News Administration of Erdosteine After Severe Course of COVID-19 in the Early Period After Patient Discharge From Medical Facility
Erdosteine is a mucomodulatory drug used in the therapy of various acute and chronic respiratory diseases. Its mechanism of action is considered complex based on available evidence, encompassing antioxidant and antibacterial effects along with its mucolytic effect. Two clinical studies assessed changes in respiratory distress parameters and quality of life in patients taking this medication in the early period after discharge from medical facilities where they were hospitalized for severe COVID-19 (respiratory failure, pneumonia).